KRAS mutant CRC cells have been reported that it could promote tumour progression and induce resistance to cetuximab therapy [28]; however, there is no effective treatment to specifically treat cancers expressing KRAS mutations [29, 30]. The gene discussed is KRAS; the disease is colorectal carcinoma.